New study to reveal hidden toll of breast cancer drugs on fertility
NCT ID NCT07527819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 75 women aged 18-42 with early-stage triple-negative breast cancer who are receiving chemotherapy plus immunotherapy before surgery. Researchers will measure hormone levels, track menstrual patterns, and use questionnaires to see how treatment affects ovarian function and fertility. No extra drugs are given—participants receive standard care. Results may help doctors better counsel patients about fertility risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors understand the impact of these treatments on ovarian health and fertility, guiding future care and counseling for young women with breast cancer.
What could go wrong
This is an observational study, not a treatment trial. It only collects data and does not test any new therapy, so it cannot directly improve outcomes. Results may take years to influence practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
Contact Email: •••••@•••••
Contact
-
Eastern Health
Box Hill, Victoria, 3128, Australia
Contact Email: •••••@•••••
Contact
-
Icon Cancer Centre
Hobart, Tasmania, 7000, Australia
Contact Email: •••••@•••••
Contact
-
Lyell McEwin Hospital
Adelaide, South Australia, 5112, Australia
Contact Email: •••••@•••••
Contact
-
Mater Hospital Sydney
Sydney, New South Wales, 2060, Australia
Contact Email: •••••@•••••
Contact
-
Monash Health
Clayton, Victoria, 3168, Australia
Contact Email: •••••@•••••
Contact
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Contact Email: •••••@•••••
Contact
-
Royal Melbourne Hospital
Melbourne, Victoria, 3052, Australia
Contact Email: •••••@•••••
Contact
-
Sir Charles Gairdner Hospital
Nedlands, Washington, 6009, Australia
Contact Email: •••••@•••••
Contact